BOT 0.00% 32.5¢ botanix pharmaceuticals ltd

Also can others please confirm or comment on the below:Here's...

  1. 1,296 Posts.
    lightbulb Created with Sketch. 246
    Also can others please confirm or comment on the below:

    Here's the sales curve for Japan:
    Fy 2021 950 million yen
    Fy 2022 1,257 million yen
    Fy 2023 1,812 million yen
    Fy 2024 plan 2,200 million yen.

    It costs ¥4,874 yen per bottle (USD $46.74)

    Which is approximately a 2 week supply.

    The sales price per bottle in the US will be $750 USD.

    So in FY21 in Japan they sold 194,000 bottles. (950million ÷ 4,874) The first year Ecclock (Sofdra) was available.

    If they match that first year of sales from Japan in the U.S. that would equate to $145 million USD gross.

    No royalties are due to any 3rd party.


    Hence you can see why some are predicting $2 - $5 a share.

    Are the receipts from customers figures which show up on the quarterly reports solely monies from the 5% royalties due to BOT for Ecclock Kaken Japan?
    Last edited by Rorbag: 23/06/24
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
32.5¢
Change
0.000(0.00%)
Mkt cap ! $588.2M
Open High Low Value Volume
32.5¢ 33.5¢ 32.5¢ $1.302M 3.974M

Buyers (Bids)

No. Vol. Price($)
14 713153 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 215665 6
View Market Depth
Last trade - 16.10pm 11/07/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.